ArticleCancer cell international2025
Integrating bulk RNA-seq, scRNA-seq, and spatial transcriptomics data to identify novel post-translational modification-related molecular subtypes and therapeutic responses in hepatocellular carcinoma.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- ROS-Centered Transcriptomic Regulatory Networks Linking Salinity Stress, Antioxidant Defense and Processability Traits inCurrent issues in molecular biology · 2026Review
- Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026Review
- Multi-Scale Transcriptomics Redefining the Tumor Immune Microenvironment.Biotech (Basel (Switzerland)) · 2026Review
- Unveiling the hidden regulators: how post-translational modifications influence the progression and treatment of hepatocellular carcinoma.Frontiers in oncology · 2026Review
- Multimodal analysis reveals potential association of CDH13 with endothelial cells and its overexpression in hepatocellular carcinoma.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) poses considerable difficulties regarding the prognosis and the assessment of treatment efficacy. Additionally, while it is recognized that post-translational modification (PTM) plays a crucial role in modulating HCC progression, their specific prognostic implications in HCC have not been thoroughly investigated.
methods21 types of PTM (acetylation, succinylation, malonylation, crotonylation, β-hydroxybutyrylation, lactylation, palmitoylation, myristoylation, SUMOylation, NEDDylation, ISGylation, ATG8ylation, FAT10ylation, UFMylation, methylation, glycosylation, biotinylation, S-nitrosylation, phosphorylation, ubiquitination, deubiquitination) were generated consensus cluster. Then, WGCNA was utilized to identify module genes. Finally, a machine learning approach was employed to create PTM.score.
resultsThis analysis revealed two distinct subtypes of PTMs, each characterized by unique molecular signatures. By integrating different categories of genes, including prognosis-related DEGs, module genes, and PTM-related genes, 15 hub genes were identified, and a PTM.score was developed. PTM.score was rigorously validated across independent external cohorts (TCGA-LIHC, LIRI-JP, GSE10143, GSE14520, GSE27150, GSE36376, and GSE76427) and an in-house cohort, demonstrating its reliability and potential applicability. In addition, patients categorized with a low PTM.score displayed a TME that was more actively engaged, which corresponded with a poor prognosis. Furthermore, these patients demonstrated a high level of responsiveness to immunotherapy interventions. Furthermore, an examination using scRNA-seq and spatial transcriptomics indicated that patients with low PTM.score exhibited heightened cell proliferation and malignancy.
conclusionThis novel PTM-related prognostic signature could effectively assess the prognosis and therapeutic responses of HCC patients, providing new perspectives for individualized treatment for the patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.